|Table of Contents|

Correlation between GTSE1 levels in peripheral blood mononuclear cells and the prognosis of epithelial ovarian cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 12
Page:
2308-2314
Research Field:
Publishing date:

Info

Title:
Correlation between GTSE1 levels in peripheral blood mononuclear cells and the prognosis of epithelial ovarian cancer
Author(s):
SUN Liyan; SONG Yongzhen; LI Yaru; LI Guifen
Department of Gynecology,Hengshui People's Hospital (Harrison International Peace Hospital),Hebei Hengshui 053000,China.
Keywords:
epithelial ovarian cancer; G2 and S phase-expressed-1; peripheral blood mononuclear cells; prognosis
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2023.12.024
Abstract:
Objective:To investigate the relationship between G2 and S phase-expressed-1 (GTSE1) in peripheral blood mononuclear cells and the prognosis of epithelial ovarian cancer (EOC).Methods:GEPIA and Kaplan-Meier Plotter were used to analyze the expression of GTSE1 in ovarian cancer tissues and its relationship with prognosis.126 patients with EOC (EOC group) in our hospital from April 2017 to October 2020 and 40 healthy check-ups without EOC (control group) during the same period were selected as study subjects.Peripheral blood mononuclear cells were isolated by Ficoll density gradient centrifugation.GTSE1 level was detected by Western blotting.Spearman correlation analysis of the relationship between GTSE1 level in EOC tissues and GTSE1 level in peripheral blood mononuclear cells was performed.The prognosis of EOC was monitored,and the risk factors for the prognosis of EOC were analyzed using COX regression.Results:GEPIA and Kaplan-Meier Plotter analysis showed that the level of GTSE1 in ovarian cancer tissues was higher than that in normal ovarian tissues (P<0.05),and the median progression-free survival time of ovarian cancer patients with low level of GTSE1 was higher than that of ovarian cancer patients with high level of GTSE1 (P<0.05).During follow-up,98 cases (77.8%) relapsed,including 65 cases of platinum-sensitive type and 33 cases of platinum-resistant type.41 cases (32.5%) died.GTSE1 mRNA and GTSE1 protein level in peripheral blood mononuclear cells were higher in the EOC group than that in the control group (P<0.001).There was a positive correlation between GTSE1 level in cancer tissues and GTSE1 level in peripheral blood mononuclear cells of EOC patients (rs=0.225,P=0.011).The level of GTSE1 in patients with stage Ⅰ-Ⅱ according to International Federation of Gynecology and Obstetrics (FIGO) was lower than that in patients with stage Ⅲ-Ⅳ (P<0.001).The level of GTSE1 in non-relapsed patients was lower than that in platinum-sensitive and platinum-resistant patients (P<0.05).The level of GTSE1 in survival patients was lower than that in death patients (P<0.001).The recurrence-free survival time and overall survival time of patients with high GTSE1 level were lower than those of patients with low GTSE1 level (P<0.001).COX regression analysis showed that high FIGO stage (HR=2.110,95%CI:1.465~3.038,P<0.001.HR=2.261,95%CI:1.212~4.216,P=0.011),initial surgical residual foci>1 cm (HR=1.724,95%CI:1.130~2.631,P=0.012.HR=2.465,95%CI:1.246~4.874,P=0.010) and GTSE1>1.29 (HR=2.071,95%CI:1.304~3.291,P=0.002.HR=5.634,95%CI:2.410~13.169,P<0.001) were independent risk factors for EOC prognosis (recurrence and survival),and bevacizumab (HR=0.293,95%CI:0.116~0.738,P=0.010.HR=0.141,95%CI:0.056~0.357,P<0.001) was an independent protective factor for EOC prognosis.Conclusion:High level of GTSE1 in peripheral blood mononuclear cells from EOC patients suggests a high risk of poor prognosis.

References:

[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2] SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2021［J］.CA Cancer J Clin,2021,71(1):7-33.
[3] 中国抗癌协会妇科肿瘤专业委员会.卵巢恶性肿瘤诊断与治疗指南(2021年版)［J］.中国癌症杂志,2021,31(6):490-500. Gynecologic Oncology Committee of China Anti-Cancer Association.Guidelines for the diagnosis and treatment of ovarian malignancies (2021 edition)［J］.Chin Oncol,2021,31(6):490-500.
[4] 李真,蔡雄伟,阎萍,等.卵巢上皮性癌患者预后列线图预测模型的建立与应用［J］.中华妇产科杂志,2022,57(3):190-197. LI Z,CAI XW,YAN P,et al.Establishment and application of a nomogram model for prognostic risk prediction in patients with epithelial ovarian cancer［J］.Chin J Obstet Gynecol,2022,57(3):190-197.
[5] PAKVISAL N,KONGKAVITOON P,SATHITRUANGSAK C,et al.Differential expression of immune-regulatory proteins C5AR1,CLEC4A and NLRP3 on peripheral blood mononuclear cells in early-stage non-small cell lung cancer patients［J］.Sci Rep,2022,12(1):18439.
[6] YAN Z,GU YY,HU XD,et al.Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism［J］.Oncol Lett,2020,20(3):3035-3045.
[7] SINGH D,SCHMIDT N,MLLER F,et al.Destabilization of long astral microtubules via Cdk1-dependent removal of GTSE1 from their plus ends facilitates prometaphase spindle orientation［J］.Curr Biol,2021,31(4):766-781.
[8] GUO W,ZHU J,ZHU Y,et al.G2 and S phase-expressed-1 acts as a putative tumor promoter in cervical cancer by enhancing Wnt/β-catenin signaling via modulation of GSK-3β［J］.Environ Toxicol,2021,36(8):1628-1639.
[9] LI SS,CHEN DM,CHEN LB,et al.GTSE1 promotes SNAIL1 degradation by facilitating its nuclear export in hepatocellular carcin oma cells［J］.Mol Med Rep,2021,23(6):454.
[10] LEI X,DU L,ZHANG P,et al.Knockdown GTSE1 enhances radiosensitivity in non-small-cell lung cancer through DNA damage repair pathway［J］.J Cell Mol Med,2020,24(9):5162-5167.
[11] KUROKI L,GUNTUPALLI SR.Treatment of epithelial ovarian cancer［J］.BMJ,2020,371:m3773.
[12] LIN F,XIE YJ,ZHANG XK,et al.GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner［J］.J Exp Clin Cancer Res,2019,38(1):152.
[13] ZHANG F,MENG J,JIANG H,et al.GTSE1 facilitates the malignant phenotype of lung cancer cells via activating AKT/mTOR signaling［J］.Anal Cell Pathol (Amst),2021,2021:5589532.
[14] OTTAVIANO M,GIUNTA EF,RESCIGNO P,et al.The enigmatic role of TP53 in germ cell tumours:are we missing something［J］.Int J Mol Sci,2021,22(13):7160.
[15] DENG J,BAI X,FENG X,et al.Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression［J］.BMC Cancer,2019,19(1):618.
[16] GUO C,GUO L,PENG C,et al.p53-driven replication stress in nucleoli of malignant epithelial ovarian cancer［J］.Exp Cell Res,2022,417(2):113225.
[17] ZI D,LI Q,XU CX,et al.CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma［J］.Aging (Albany NY),2022,14(11):4673-4698.
[18] GOU R,ZHU L,ZHENG M,et al.Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer:based on the comprehensive analysis of Annexins［J］.J Transl Med,2019,17(1):275.
[19] WANG C,WEN A,QIAO J,et al.High expression of RING finger protein 126 predicts unfavorable prognosis of epithelial ovarian cancer［J］.Med Sci Monit,2020,26:e921370.
[20] PEI ML,ZHAO ZX,SHUANG T.Dysregulation of lnc-SNHG1 and miR-216b-5p correlate with chemoresistance and indicate poor prognosis of serous epithelial ovarian cancer［J］.J Ovarian Res,2020,13(1):144.
[21] TEWARI KS,BURGER RA,ENSERRO D,et al.Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer［J］.J Clin Oncol,2019,37(26):2317-2328.
[22] PIGNATA S,LORUSSO D,JOLY F,et al.Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer:a randomised,phase 3 trial［J］.Lancet Oncol,2021,22(2):267-276.

Memo

Memo:
河北省卫生健康委医学科学研究项目（编号：20211492）
Last Update: 1900-01-01